https://mindmedicinelaw.com/briefing/psilocybin-therapy-for-alcohol-use-disorder-evidence-review-and-policy-implicati-20261106-56994The Psychedelic Journalen2026-11-07T15:05:51.951058+00:00Psilocybin Therapy for Alcohol Use Disorder: Evidence Review and Policy Implicationspsilocybin-assisted therapy, alcohol use disorder, systematic review, randomized controlled trials, functional unblinding, clinical trial design, regulatory policy, addiction treatment, psychedelic research, evidence certaintyhttps://mindmedicinelaw.com/briefing/psychologists-seek-apa-psychedelic-science-division-policy-and-practice-implicat-20261106-56944The Psychedelic Journalen2026-11-06T22:08:03.118449+00:00Psychologists Seek APA Psychedelic Science Division: Policy and Practice Implicationsapa psychedelic division, psychologists petition, psychedelic research policy, clinical training psychedelics, institutional acceptance psychedelics, ethical standards psychedelic care, research funding psychedelics, professional legitimacy psychologyhttps://mindmedicinelaw.com/briefing/psilocybin-s-astrocytic-modulation-in-nucleus-accumbens-new-mechanistic-insights-20261105-57106The Psychedelic Journalen2026-11-07T15:06:04.917850+00:00Psilocybin’s Astrocytic Modulation in Nucleus Accumbens: New Mechanistic Insightspsilocybin, astrocytes, nucleus accumbens, gene regulation, psychedelic mechanisms, clinical trial design, glial cells, FDA policy, psychiatric disordershttps://mindmedicinelaw.com/briefing/audit-finds-mdma-and-psilocybin-trials-rarely-test-trim-hypothesis-3-at-12-month-20261105-56853The Psychedelic Journalen2026-11-06T22:08:31.080598+00:00Audit Finds MDMA and Psilocybin Trials Rarely Test TRIM Hypothesis 3 at 12 Monthsmdma-assisted therapy, psilocybin therapy, randomized controlled trials, trauma-resilience integration model, trim hypothesis 3, long-term follow-up, comparator arms, clinical evidence gaps, psychedelic research, regulatory standardshttps://mindmedicinelaw.com/briefing/psilocybin-vs-ibogaine-rural-health-systems-face-strategic-choice-20261105-56832The Psychedelic Journalen2026-11-06T22:08:17.519080+00:00Psilocybin vs Ibogaine: Rural Health Systems Face Strategic Choicepsilocybin therapy, ibogaine, rural health systems, opioid use disorder, behavioral health, fda regulation, clinical evidence, psychedelic-assisted therapy, service delivery modelshttps://mindmedicinelaw.com/briefing/psilocybin-s-astrocytic-modulation-of-nucleus-accumbens-mechanism-and-implicatio-20261105-56833The Psychedelic Journalen2026-11-06T22:07:18.107581+00:00Psilocybin’s Astrocytic Modulation of Nucleus Accumbens: Mechanism and Implicationspsilocybin, nucleus accumbens, astrocytes, GABA homeostasis, NFATc4, ALDH5A1, psychedelic mechanism, translational neuroscience, mood disorders, addiction researchhttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-emotional-evidence-integration-new-insights-for-translation-20261104-56869The Psychedelic Journalen2026-11-06T22:09:05.305468+00:00Ketamine’s Impact on Emotional Evidence Integration: New Insights for Translational Psychiatryketamine, emotional evidence integration, affective disorders, clinical trial design, nmda receptor antagonist, environmental volatility, translational psychiatry, neurocognitive mechanisms, psychedelic researchhttps://mindmedicinelaw.com/briefing/oral-ketamine-for-resistant-depression-evidence-protocols-and-policy-gaps-20261104-56877The Psychedelic Journalen2026-11-06T22:08:53.538518+00:00Oral Ketamine for Resistant Depression: Evidence, Protocols, and Policy Gapsoral ketamine, treatment-resistant depression, suicidality, dosing protocols, randomized controlled trials, psychiatric policy, adverse effects, clinical guidelines, regulatory approvalhttps://mindmedicinelaw.com/briefing/phase-2-trial-itbs-extends-ketamine-response-in-trd-patients-20261104-56879The Psychedelic Journalen2026-11-06T22:08:42.690902+00:00Phase 2 Trial: iTBS Extends Ketamine Response in TRD Patientstreatment-resistant depression, ketamine, intermittent theta burst stimulation, iTBS, clinical trial, phase 2, brain connectivity, neuromodulation, combination therapy, fMRIhttps://mindmedicinelaw.com/briefing/oral-ketamine-in-burn-wound-care-clinical-evidence-and-policy-outlook-20261104-56739The Psychedelic Journalen2026-11-05T22:06:03.473441+00:00Oral Ketamine in Burn Wound Care: Clinical Evidence and Policy Outlookoral ketamine, burn wound care, pain management, acute care, clinical protocols, off-label use, opioid alternatives, regulatory policy, hospital formulary, NMDA antagonisthttps://mindmedicinelaw.com/briefing/polydrug-use-and-ptsd-insights-from-mass-trauma-survivors-in-israel-20261103-56854The Psychedelic Journalen2026-11-07T15:06:46.253539+00:00Polydrug Use and PTSD: Insights from Mass Trauma Survivors in Israelpolydrug use, ptsd, mass trauma, psychedelics, recreational motives, self-medication, nova festival, public health, substance use patternshttps://mindmedicinelaw.com/briefing/bdnf-pathway-as-a-target-for-treatment-resistant-depression-mechanistic-insights-20261103-56880The Psychedelic Journalen2026-11-07T15:06:33.587941+00:00BDNF Pathway as a Target for Treatment-Resistant Depression: Mechanistic Insights and Clinical Implicationsbdnf, treatment-resistant depression, neuroplasticity, psychedelic research, precision psychiatry, epigenetics, clinical trial design, biomarkers, genetic polymorphismhttps://mindmedicinelaw.com/briefing/ketamine-s-anti-dyskinetic-effects-in-female-parkinson-s-models-preclinical-evid-20261103-56883The Psychedelic Journalen2026-11-07T15:06:18.493522+00:00Ketamine’s Anti-Dyskinetic Effects in Female Parkinson’s Models: Preclinical Evidence and Implicationsketamine, parkinson's disease, l-dopa-induced dyskinesia, sex differences, preclinical models, female rats, clinical trial design, regulatory policy, neuropharmacologyhttps://mindmedicinelaw.com/briefing/discovery-of-naadp-lysosomal-pathway-in-5-ht2a-psychedelic-signaling-20261103-56881The Psychedelic Journalen2026-11-06T22:07:41.174356+00:00Discovery of NAADP-Lysosomal Pathway in 5-HT2A Psychedelic Signaling5-ht2a receptor, naadp, lysosomal calcium, psychedelic mechanism, neuroplasticity, hallucinogenic effects, drug development, clinical translation, intracellular signalinghttps://mindmedicinelaw.com/briefing/psilocybin-therapy-for-cancer-distress-systematic-review-insights-20261103-56838The Psychedelic Journalen2026-11-06T22:07:29.939087+00:00Psilocybin Therapy for Cancer Distress: Systematic Review Insightspsilocybin-assisted therapy, cancer-related distress, systematic review, existential distress, depression and anxiety, palliative care, clinical trial design, adverse events, regulatory policy, psychedelic researchhttps://mindmedicinelaw.com/briefing/systematic-review-no-effective-drugs-for-prolonged-grief-disorder-20261102-56842The Psychedelic Journalen2026-11-07T15:07:39.751085+00:00Systematic Review: No Effective Drugs for Prolonged Grief Disorderprolonged grief disorder, systematic review, pharmacological treatment, psychedelic-assisted therapy, clinical trials, mental health policy, bereavement, antidepressants, regulatory implicationshttps://mindmedicinelaw.com/briefing/ohio-state-launches-psilocybin-trial-for-depression-in-lung-cancer-patients-20261102-56943The Psychedelic Journalen2026-11-07T15:07:25.891657+00:00Ohio State Launches Psilocybin Trial for Depression in Lung Cancer Patientspsilocybin therapy, lung cancer depression, ohio state university trial, oncology psychedelics, clinical trial phase, palliative care innovation, fda regulation, mental health in cancer, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/music-therapy-and-psychedelics-in-psychiatric-care-review-and-implications-20261102-56844The Psychedelic Journalen2026-11-07T15:07:13.171947+00:00Music Therapy and Psychedelics in Psychiatric Care: Review and Implicationsmusic therapy, psychedelic treatment, psychiatric disorders, clinical trial design, depression, anxiety, ptsd, neural mechanisms, treatment protocolshttps://mindmedicinelaw.com/briefing/enantioselective-ketamine-analysis-in-pink-cocaine-forensic-and-policy-implicati-20261102-56888The Psychedelic Journalen2026-11-07T15:07:00.180605+00:00Enantioselective Ketamine Analysis in 'Pink Cocaine': Forensic and Policy Implicationsketamine enantiomers, pink cocaine, forensic drug analysis, capillary electrophoresis, high-performance liquid chromatography, drug diversion, chiral surveillance, public health monitoring, law enforcement, illicit drug markethttps://mindmedicinelaw.com/briefing/ketamine-bladder-toxicity-clinical-and-policy-implications-global-2026-20261101-56899The Psychedelic Journalen2026-11-07T15:07:54.278016+00:00Ketamine Bladder Toxicity: Clinical and Policy Implications (Global, 2026)ketamine bladder toxicity, urinary tract complications, psychedelic therapy safety, bladder dysfunction, clinical protocols, regulatory policy, risk mitigation, psychiatric indications, adverse events monitoringhttps://mindmedicinelaw.com/briefing/fireside-project-s-25-000-psychedelic-support-dataset-us-evidence-for-policy-and-20261030-56851The Psychedelic Journalen2026-11-06T22:07:51.965600+00:00Fireside Project's 25,000+ Psychedelic Support Dataset: US Evidence for Policy and Practicefireside project, psychedelic support, harm reduction, peer support dataset, psilocybin use, cannabis distress, public health policy, nonclinical psychedelic use, volunteer training, epidemiologyhttps://mindmedicinelaw.com/briefing/systematic-review-psychedelics-and-psychosis-risk-1984-2025-20261027-56768The Psychedelic Journalen2026-11-05T22:05:07.862575+00:00Systematic Review: Psychedelics and Psychosis Risk (1984–2025)psychedelics, psychosis risk, systematic review, clinical trial safety, public health policy, screening protocols, adverse event reporting, neuroscience, regulatory guidancehttps://mindmedicinelaw.com/briefing/ketamine-s-expanding-medical-profile-policy-and-research-implications-global-202-20261023-56749The Psychedelic Journalen2026-11-05T22:05:31.325598+00:00Ketamine’s Expanding Medical Profile: Policy and Research Implications (Global, 2026)ketamine, analgesic mechanisms, psychiatric effects, antitumour activity, immunomodulation, clinical trials, regulatory policy, off-label use, risk-benefit assessment, biomarker integrationhttps://mindmedicinelaw.com/briefing/ketamine-derivative-s-antidepressant-effects-via-adenosine-ncbi-study-20261022-56756The Psychedelic Journalen2026-11-05T22:05:48.350792+00:00Ketamine Derivative’s Antidepressant Effects via Adenosine: NCBI Studyketamine derivative, adenosine signaling, antidepressant mechanism, rapid-acting antidepressants, mood disorders, clinical trials, ncbi study, nmda antagonism, drug development, psychiatric therapeuticshttps://mindmedicinelaw.com/briefing/cost-effectiveness-of-ketamine-versus-ect-in-us-depression-care-20261022-56780The Psychedelic Journalen2026-11-05T22:04:52.280854+00:00Cost-Effectiveness of Ketamine Versus ECT in US Depression Careketamine, electroconvulsive therapy, treatment-resistant depression, cost-effectiveness, insurance coverage, clinical guidelines, mental health policy, health economics, psychiatric interventions